SA519401954B1 - تركيبة صيدلانية للوقاية من أو معالجة سرطان تشتمل على صورة متعددة الشكل البلوري من تترا أرسينيك هيكسوكسويد - Google Patents

تركيبة صيدلانية للوقاية من أو معالجة سرطان تشتمل على صورة متعددة الشكل البلوري من تترا أرسينيك هيكسوكسويد

Info

Publication number
SA519401954B1
SA519401954B1 SA519401954A SA519401954A SA519401954B1 SA 519401954 B1 SA519401954 B1 SA 519401954B1 SA 519401954 A SA519401954 A SA 519401954A SA 519401954 A SA519401954 A SA 519401954A SA 519401954 B1 SA519401954 B1 SA 519401954B1
Authority
SA
Saudi Arabia
Prior art keywords
prevention
treatment
cancer
pharmaceutical composition
hexoxide
Prior art date
Application number
SA519401954A
Other languages
English (en)
Inventor
الثالث جو باى
زينجلين ليان
Original Assignee
شيماس كو . ليمتد
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by شيماس كو . ليمتد filed Critical شيماس كو . ليمتد
Publication of SA519401954B1 publication Critical patent/SA519401954B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/285—Arsenic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/36—Arsenic; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01G—COMPOUNDS CONTAINING METALS NOT COVERED BY SUBCLASSES C01D OR C01F
    • C01G28/00—Compounds of arsenic
    • C01G28/005—Oxides; Hydroxides; Oxyacids
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00—Crystal-structural characteristics
    • C01P2002/60—Compounds characterised by their crystallite size
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2002/00—Crystal-structural characteristics
    • C01P2002/70—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data
    • C01P2002/72—Crystal-structural characteristics defined by measured X-ray, neutron or electron diffraction data by d-values or two theta-values, e.g. as X-ray diagram
    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
    • C01P2006/00—Physical properties of inorganic compounds
    • C01P2006/80—Compositional purity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبة صيدلانية للوقاية من أو معالجة السرطان cancer وطريقة لإنتاجها، وتشتمل التركيبة على هيكسوكسيد تتراسينيك tetraarsenic hexoxide وحيث يكون به محتوى الصورة متعددة الأشكال المتبلرة أ (As4O6-a ) هو 99٪ أو أكثر. وتعرض تركيبة الاختراع الحالي تأثير تثبيط تكاثر خلية السرطان cancer cell وبالتالي يمكن أن تكون مفيدة في شكل عقار مضاد للسرطان anticancer drug. شكل10
SA519401954A 2016-12-09 2019-06-09 تركيبة صيدلانية للوقاية من أو معالجة سرطان تشتمل على صورة متعددة الشكل البلوري من تترا أرسينيك هيكسوكسويد SA519401954B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020160167222A KR101844050B1 (ko) 2016-12-09 2016-12-09 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물
PCT/KR2017/014082 WO2018105972A1 (ko) 2016-12-09 2017-12-04 육산화사비소의 결정다형을 포함하는 암 예방 또는 치료용 약학 조성물

Publications (1)

Publication Number Publication Date
SA519401954B1 true SA519401954B1 (ar) 2024-01-29

Family

ID=62187734

Family Applications (1)

Application Number Title Priority Date Filing Date
SA519401954A SA519401954B1 (ar) 2016-12-09 2019-06-09 تركيبة صيدلانية للوقاية من أو معالجة سرطان تشتمل على صورة متعددة الشكل البلوري من تترا أرسينيك هيكسوكسويد

Country Status (16)

Country Link
US (1) US11191779B2 (ar)
EP (1) EP3552611A4 (ar)
JP (1) JP6824409B2 (ar)
KR (1) KR101844050B1 (ar)
CN (2) CN108606979A (ar)
AU (1) AU2017371040B2 (ar)
BR (1) BR112019010999A2 (ar)
CA (1) CA3044514C (ar)
CL (1) CL2019001565A1 (ar)
IL (1) IL267132B (ar)
MX (1) MX392459B (ar)
MY (1) MY197417A (ar)
PH (1) PH12019501292A1 (ar)
SA (1) SA519401954B1 (ar)
WO (1) WO2018105972A1 (ar)
ZA (1) ZA201903059B (ar)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58514B1 (sr) 2012-06-13 2019-04-30 Incyte Holdings Corp Supstituisana triciklična jedinjenja kao inhibitori fgfr
PH12015502383B1 (en) 2013-04-19 2023-02-03 Incyte Holdings Corp Bicyclic heterocycles as fgfr inhibitors
TWI712601B (zh) 2015-02-20 2020-12-11 美商英塞特公司 作為fgfr抑制劑之雙環雜環
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
HRP20241288T1 (hr) 2018-05-04 2024-12-06 Incyte Corporation Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
AU2019262579B2 (en) 2018-05-04 2024-09-12 Incyte Corporation Salts of an FGFR inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en) 2019-07-09 2023-02-28 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
WO2021067374A1 (en) 2019-10-01 2021-04-08 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3157361A1 (en) 2019-10-14 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3163875A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
JP7832891B2 (ja) 2019-12-04 2026-03-18 インサイト・コーポレイション Ｆｇｆｒ阻害剤の誘導体
US12012409B2 (en) 2020-01-15 2024-06-18 Incyte Corporation Bicyclic heterocycles as FGFR inhibitors
KR102240693B1 (ko) * 2020-05-18 2021-04-15 주식회사 케마스 육산화사비소를 포함하는 코로나바이러스 감염증의 예방 또는 치료용 약학조성물
WO2022221170A1 (en) 2021-04-12 2022-10-20 Incyte Corporation Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
US11939331B2 (en) 2021-06-09 2024-03-26 Incyte Corporation Tricyclic heterocycles as FGFR inhibitors
CA3220155A1 (en) 2021-06-09 2022-12-15 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2025165158A1 (ko) * 2024-01-29 2025-08-07 배일주 육산화사비소(As4O6)를 포함하는 방광암 예방 또는 치료용 약학 조성물
KR20250118232A (ko) 2024-01-29 2025-08-05 배일주 육산화사비소(As4O6)를 포함하는 방광암 예방 또는 치료용 약학 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875451B2 (en) 1997-10-15 2005-04-05 Polarx Biopharmaceuticals Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
TR200002243T2 (tr) * 1997-11-10 2000-12-21 Memorial Sloan-Kettering Cancer Center Arsenik trioksitin hazırlanması için işlem ve bunların kanser tedavisi için kullanımı.
US7261906B2 (en) 1998-05-08 2007-08-28 Ill-Ju Bae Anti-cancer therapy agent of arsenic hexoxide (As4O6) of a natural chemical substance and its pharmaceutical composition
KR100272835B1 (ko) 1998-05-08 2000-11-15 배일주 천연 화학물질 육산화사비소의 신규한 항종양 치료제로서의 용도 및 그 약학적 조성물
DE19821508C2 (de) 1998-05-13 2002-08-29 Trelleborg Automotive Tech Ct Zweikammer-Motorlager
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
KR20020095835A (ko) 2001-06-16 2002-12-28 배일주 아폽토시스 유도제
TWI296527B (en) * 2003-04-23 2008-05-11 Inst Of Nuclear Energy Res Rocaec Radioactive aesenic-containing compounds and their uses in the treatment of tumors
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
KR101572529B1 (ko) 2008-11-14 2015-11-27 배일주 암 치료를 위한 육산화사비소의 병용요법
CN117899029A (zh) 2015-02-01 2024-04-19 希洛斯医药品股份有限公司 用于在患者中口服施用的含有砷的高表面积冻干组合物
KR101755556B1 (ko) 2016-11-18 2017-07-07 주식회사 케마스 육산화사비소의 결정다형을 포함하는 뇌암 예방 또는 치료용 약학 조성물 및 이의 제조방법
KR101834366B1 (ko) 2016-11-21 2018-03-05 주식회사 케마스 육산화사비소의 결정다형을 포함하는 유방암 예방 또는 치료용 약학 조성물 및 이의 제조방법
KR101844049B1 (ko) 2016-12-05 2018-03-30 주식회사 케마스 육산화사비소의 결정다형을 포함하는 간암 예방 또는 치료용 약학 조성물

Also Published As

Publication number Publication date
US20200000846A1 (en) 2020-01-02
JP6824409B2 (ja) 2021-02-03
MX2019006622A (es) 2019-08-01
IL267132A (en) 2019-10-31
MY197417A (en) 2023-06-16
CN108606979A (zh) 2018-10-02
WO2018105972A1 (ko) 2018-06-14
PH12019501292A1 (en) 2019-12-02
CA3044514C (en) 2021-06-15
CL2019001565A1 (es) 2020-02-21
EP3552611A1 (en) 2019-10-16
ZA201903059B (en) 2020-09-30
CA3044514A1 (en) 2018-06-14
JP2020504088A (ja) 2020-02-06
MX392459B (es) 2025-03-24
CN116672363A (zh) 2023-09-01
AU2017371040A1 (en) 2019-06-20
US11191779B2 (en) 2021-12-07
BR112019010999A2 (pt) 2019-10-15
EP3552611A4 (en) 2020-06-24
AU2017371040B2 (en) 2020-05-07
IL267132B (en) 2022-05-01
KR101844050B1 (ko) 2018-05-14

Similar Documents

Publication Publication Date Title
SA519401954B1 (ar) تركيبة صيدلانية للوقاية من أو معالجة سرطان تشتمل على صورة متعددة الشكل البلوري من تترا أرسينيك هيكسوكسويد
PH12019501220A1 (en) Pharmaceutical composition for preventing or treating liver cancer, comprising tetraarsenic hexoxide crystalline polymorph
SA519401785B1 (ar) تركيبة صيدلانية للوقاية من سرطان الثدي أو علاجه تشتمل على متعدد أشكال بلورية لسداسي أكسيد الزرنيخ الرباعي، وطريقة لإنتاجها
SA519401787B1 (ar) تركيبة صيدلانية للوقاية من سرطان المخ أو علاجه تشتمل على متعدد أشكال بلورية لسداسي أكسيد الزرنيخ الرباعي، وطريقة لتحضيرها
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
UA118380C2 (uk) Заміщені сполуки дигідроізохінолінону
MX2016007801A (es) Pirimidopirimidinonas utiles como iniciadores de wee-1 cinasa.
MY199711A (en) Bicyclic heterocycles as fgfr inhibitors
MX366623B (es) 5-(3,5-dimetilisoxazol-4-il)indolina-2-onas sustituidas.
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
EA033238B1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
SG10201805890QA (en) Compositions and methods for treatment of abnormal cell growth
PH12016501997B1 (en) Cycloalkyl-linked diheterocycle derivatives
MX2017004723A (es) Composicion farmaceutica para usarse en el tratamiento o la prevencion de deficiencias de vitaminas y minerales en pacientes que han sido sometidos a cirugia de derivacion gastrica.
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
MX2017014463A (es) Cabazitaxel y su uso para tratar cancer.
MX2015011126A (es) Compuestos antivirales.
TH1901003032A (th) องค์ประกอบทางเภสัชกรรมสำหรับการป้องกันหรือการรักษาโรคมะเร็งเต้านมที่ประกอบด้วยสารพหุสัณฐานรูปผลึกของเตตระอาร์ซีนิกเฮกซ์ออกไซด์และวิธีการสำหรับการผลิตสิ่งเดียวกันนี้
HK1230956A1 (en) Compositions and methods for treatment of abnormal cell growth